ArticleDiscover oncology2025
Primary pancreatic signet ring cell carcinoma: a case series from China and literature review.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
objectiveTo report on cases of primary pancreatic signet ring cell carcinoma (PSRCC) from our institution, review the published literature, and evaluate the clinicopathological characteristics. MATERIAL AND
methodsWe present a recent case of PSRCC and report 11 additional cases from China, utilizing the China National Knowledge Infrastructure (CNKI) database. The literature search encompassed publications from January 1994 to December 2023. We also performed a literature search using PubMed and Web of Science to identify cases of PSRCC outside of China and identified a total of 13 additional cases.
resultsA total of 12 cases from China were identified, with a mean age of 64 years. Among these, 11 patients (91.7%) were male, and 1 patient (8.3%) was female. The tumor was primarily located in the pancreatic head (7 cases, 57.3%), followed by the pancreatic body (3 cases, 25.0%) and tail (2 cases, 16.7%). Six patients (50%) underwent radical curative surgery, while the remaining 6 (50%) received palliative surgical treatment or chemotherapy. In the radical curative surgery group (6 patients), the longest follow-up was 23 months, with only one death reported. In contrast, all patients who received palliative treatment (6 patients) experienced short-term mortality, with the longest follow-up period being 5 months. While most patients were Chinese, similar outcomes have been reported in non-Chinese populations, indicating broader applicability.
conclusionPSRCC is a highly aggressive and extremely rare pancreatic malignancy, typically originating in the head of the pancreas. Patients diagnosed at an early stage and who undergo radical surgery demonstrate significantly prolonged survival.
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.